Pharma Firms Debate Novel Biotech Deals: How Much Competition Is Healthy?
R&D productivity is best encouraged through "benchmarking" among a firm's own drug development centers rather than external competition with licensing partners, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, said
You may also be interested in...
Large pharma companies are facing a potential "bottleneck" in early stage clinical development as they sift through new therapeutic candidates, Merck Exec VP-Worldwide Basic Research Anthony Ford-Hutchinson, PhD, told a BIO-Windhover conference April 15 in Washington, D.C
GlaxoSmithKline's R&D productivity program has experienced some early successes in the number of compounds coming out of the early-stage pipeline
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011